Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally

What happened: Baillie Gifford's Q3 2026 US Equity Growth letter named Moderna (NASDAQ:MRNA) its largest positive contributor over the past year, citing positive late-stage results for its personalised melanoma treatment alongside Keytruda in August. Key numbers: MRNA closed at $225.00 on October 09, 2026, with an $89.83 billion market Why it matters: The melanoma data gave evidence that Moderna's mRNA platform can extend beyond infectious diseases, and shares rose sharply on the news. Baillie Gifford still calls Moderna an early-stage, volatile opportunity, reflected in its position size. Market: +1.2% by next close ($216.25 on Oct 13), +633.3% YTD

Baillie Gifford's Q3 2026 US Equity Growth letter named Moderna (NASDAQ:MRNA) its largest positive contributor over the past year, citing positive late-stage results for its personalised melanoma treatment alongside Keytruda in August.

The melanoma data gave evidence that Moderna's mRNA platform can extend beyond infectious diseases, and shares rose sharply on the news. Baillie Gifford still calls Moderna an early-stage, volatile opportunity, reflected in its position size. Market: +1.2% by next close ($216.25 on Oct 13), +633.3% YTD